Detailed explanation of the treatment cycle of obeticholic acid

Obeticholic acid (Obeticholic acid) is an innovative drug that has emerged in the treatment of liver diseases with its unique mechanism of action. As the first agonist that selectively binds to the farnesoid X receptor (FXR), obeticholic acid can precisely regulate bile acid metabolism in the liver, providing a new treatment strategy for cholestatic diseases such as primary biliary cholangitis (PBC).

Obeticholic acid effectively reduces liver exposure to toxic bile acids by directly and indirectly inhibiting bile acid production in the liver while increasing bile flow. These effects not only help reduce the substantial damage to the liver caused by bile acids, but also significantly improve the patient's biochemical indicators and delay the progression of the disease.

In terms of pharmacokinetics, obeticholic acid exhibits good absorption and metabolism properties. After oral administration, obeticholic acid is rapidly absorbed and reaches peak plasma concentration within 1.5 hours, and is not affected by food intake. The drug is widely distributed in the body and has a binding rate of 99% to plasma proteins, which helps it exert a long-lasting therapeutic effect in the body. Although the impact of other highly protein-bound drugs on the pharmacokinetics of obeticholic acid is currently unclear, its metabolism and excretion processes in the body have been intensively studied.

For patients, one of the biggest concerns may be the treatment cycle of obeticholic acid. In practice, the duration of obeticholic acid use varies based on individual differences and disease conditions. For patients with primary biliary cholangitis, obeticholic acid is usually recommended as a first-line treatment and needs to be taken long-term to maintain the stability of liver function, improve cholestasis, and slow down the progression of the disease.